> Program > Scientific Program
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Viral hepatitis |
| 08:52-09:14 | Alcoholic and nonalcoholic liver disease | |
| 09:14-09:36 | Liver cirrhosis and complications | |
| 09:36-09:58 | Hepatocellular carcinoma | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speaker | 10:15-10:45 | Beyond the best with humanity and creativity |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | The application of texture quantification in hepatocellular carcinoma using CT and MRI |
| 12:47-13:09 | Next generation diagnostic pathology: Artificial intelligence-powered diagnosis and biomarker analysis | |
| 13:09-13:31 | Utilization of digital healthcare big data | |
| 13:31-13:53 | Profiling based identification and application of non-coding RNAs as biomarker for hepatocellular carcinoma | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | The assessment of NAFLD using diagnostic algorithm |
| 14:32-14:54 | The sequential application of systemic chemotherapy in advanced HCC | |
| 14:54-15:16 | The treatment of nonselective beta blocker to patients with varices: (Who, When, and Which drug) | |
| 15:16-15:38 | The selection of proper anti-viral agents to patients with CHB in each condition | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | The present and future of therapeutic vaccine for viral hepatitis B |
| 16:17-16:39 | The present and future of therapeutic or preventative vaccine for viral hepatitis C | |
| 16:39-17:01 | COVID-19 vaccination in patients with chronic liver disease | |
| 17:01-17:23 | Vaccination strategy for patients with chronic liver disease and liver transplantation | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | The role of endoscopic management in afferent loop syndrome |
| 12:47-13:09 | Novel approach for prevention of post-ESD bleeding | |
| 13:09-13:31 | Optimal use of the over-the-scope clip for treatment of GI complication | |
| 13:31-13:53 | New modalities for treatment of post-operative anastomotic leak | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Physiologic and pathologic changes of GI tract of the elderly |
| 14:32-14:54 | Atrophic gastritis and other chronic inflammation and gastric carcinogenesis | |
| 14:54-15:16 | Antithrombotic-induced upper GI injury | |
| 15:16-15:38 | NSAIDs-induced upper GI injury | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Gender perspective in esophageal cancer |
| 16:17-16:39 | Sex differences in colon cancer: Epidemiology, genetics and therapy | |
| 16:39-17:01 | Sex differences in the risk factors for hepatocellular carcinoma in Korea | |
| 17:01-17:23 | Sex matters: Impact on pathogenesis, presentation and treatment of inflammatory bowel disease | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:50 | Epidemiology |
| 08:50-09:10 | Diagnostic approach | |
| 09:10-09:30 | Novel pharmacologic treatment | |
| 09:30-09:50 | Non-medical treatment for refractory constipation | |
| 09:50-10:00 | Discussion | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:35 | Epidemiology |
| 10:35-10:55 | Pathogenesis | |
| 10:55-11:15 | Medical treatment | |
| 11:15-11:35 | Non-pharmacological treatment for functional dyspepsia | |
| 11:35-11:45 | Discussion | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Primary 3D culture-based research in upper GI cancer |
| 12:47-13:09 | Current status & future direction of AI in upper GI cancer | |
| 13:09-13:31 | Current status & future direction of immunotherapy in upper GI cancer | |
| 13:31-13:53 | The Gastric Microbiome in Gastric Cancer | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Artificial intelligence-aided colonoscopy in polyp detection and differentiation |
| 14:32-14:54 | AI assessment for the eligibility for endoscopic resection in patients with early CRC | |
| 14:54-15:16 | AI applications in colorectal cancer prognosis and prediction | |
| 15:16-15:38 | Digital pathology in CRC diagnosis: Promise and hurdles | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Treatment approaches in borderline resectable and locally advanced pancreatic cancer |
| 16:17-16:39 | Are we really making progress in the surgery of pancreatic cancer? | |
| 16:39-17:01 | New agent and combination therapy for patients with metastatic pancreatic cancer | |
| 17:01-17:23 | Novel Radiotherapy in Pancreatic Cancer | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Up-to-date of cholangioscopy: From percutaneous to SOC |
| 08:52-09:14 | Optimal endoscopic drainage strategy | |
| 09:14-09:36 | Efficacy of RFA and applying strategy | |
| 09:36-09:58 | Surgical palliation after neoadjuvant chemotherapy | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Clinical application of novel biomarker for the diagnosis of pancreatobiliary cancer |
| 10:37-10:59 | Feasibility of developing immune profiles of pancreatitis and pancreatic cancer | |
| 10:59-11:21 | NK cell-based immunotherapies in pancreato-biliary cancer | |
| 11:21-11:43 | Double spiral microfluidic device for highly elaborated formation of circulating tumor cell-neutrophil clusters through deterministic encapsulation | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:50 | Usefulness of high-resolution manometry for the management of oropharyngeal dysphagia |
| 08:50-09:10 | Functional dyspepsia -Diagnosis and treatment- | |
| 09:10-09:30 | Esophageal mucosal histopathology may help differentiate achalasia from refractory gastroesophageal reflux disease | |
| 09:30-09:40 | New parameter for quantifying bolus transit with high-resolution impedance manometry | |
| 09:40-09:50 | Assessment of esophagogastric junction in post-POEM reflux esophagitis | |
| 09:50-10:00 | Comparison of manometric diagnosis by Chicago classification version 3.0 and 4.0 on esophageal high resolution manometry | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:35 | Early intervention in IBD: Why and how? |
| 10:35-10:55 | Deep neural network for colonoscopy of ulcerative colitis | |
| 10:55-11:15 | Transmural healing: The dream or the ideal to be achieved | |
| 11:15-11:25 | Big data research: Progress makes practice in IBD | |
| 11:25-11:35 | The role of endoscopy in inflammatory bowel disease | |
| 11:35-11:45 | Clostridium innocuum in inflammatory bowel disease | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:45 | Upfront surgery for resectable/borderline-resectable pancreatic cancer |
| 12:45-13:05 | Neoadjuvant therapy for resectable/borderline-resectable pancreatic ductal adenocarcinoma | |
| 13:05-13:25 | Should we perform neoadjuvant therapy in resectable pancreatic cancer? | |
| 13:25-13:35 | Neoadjuvant chemotherapy for resectable/borderline-resectable pancreatic cancer | |
| 13:35-13:45 | The strategies for resectable / borderline-resectable pancreatic cancer | |
| 13:45-13:55 | Reshaping resectable/borderline-resectable pancreatic cancer in the era of precision medicine | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:30 | Optimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: A lesson from real-world evidence |
| 14:30-14:50 | Current status in hepatitis B management in Japan and future perspectives | |
| 14:50-15:10 | Towards Elimination of HBV Infection in Taiwan | |
| 15:10-15:20 | Identifying hepatocellular carcinoma risk of untreated chronic hepatitis B for timely antiviral intervention | |
| 15:20-15:30 | Role of host immune responses in achieving HBsAg loss | |
| 15:30-15:40 | Combined ALT/HBsAg kinetics for re-treatment decision in HBeAg-negative CHB patients with off-Nuc hepatitis flare | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | COVID-19 and Endoscopy: Impact and Countermeasures |
| 16:17-16:39 | COVID-19 and IBD | |
| 16:39-17:01 | COVID-19 and Cancer | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Radiomics-based clinical model for hepatocellular cancer |
| 12:47-13:09 | Radiomics approaches in gastric cancer and colon cancer | |
| 13:09-13:31 | Application of radiomics in inflammatory bowel disease | |
| 13:31-13:53 | The application of novel diagnostics and radiomics in the evaluation of pancreatic cystic lesions | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:30 | Application of treat-to-target strategy in clinical practice |
| 14:30-14:50 | Choosing biologic agents beyond conventional therapy: When and What? | |
| 14:50-15:10 | Optimal use of therapeutic drug monitoring | |
| 15:10-15:30 | Prevention of complications from IBD treatments | |
| 15:30-15:40 | Discussion | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:15 | Using organoids to understand colorectal cancer genetic drivers and guide treatment choice |
| 16:15-16:35 | Intestinal organoids as a tool for IBD research | |
| 16:35-16:55 | Applications of patient-derived organoids in the management of colorectal cancer | |
| 16:55-17:15 | Organoid-based regenerative and precision medicine for IBD | |
| 17:15-17:25 | Discussion | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Can endoscopic disease activity predict the clinical outcome of IBD? |
| 08:52-09:14 | Surveillance colonoscopy for dysplasia: How to optimize it in daily practice | |
| 09:14-09:36 | Colitis-associated dysplasia: Resect it or remove the entire colon? | |
| 09:36-09:58 | Role and limitation of endoscopic intervention for Crohn's strictures | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Recent guidelines of ESD for EGCa |
| 10:37-10:59 | WHO classifications of gastric cancer-pathology | |
| 10:59-11:21 | ESD vs surgery for undifferentiated EGCa | |
| 11:21-11:43 | Management after non-curative resection for EGC | |
| Date / Time | 298, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Chemoprevention of hepatocellular carcinoma: Aspirin and statin |
| 16:17-16:39 | Trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors | |
| 16:39-17:01 | Risk of gastric cancer development: Proton pump inhibitors vs histamine 2 receptor | |
| 17:01-17:23 | Severe clinical outcomes of COVID-19 associated with proton pump inhibitors | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:15 | Conventional methods for detection of colorectal cancer: Are they enough? |
| 16:15-16:35 | Up to date biomarkers for detecting colorectal cancer | |
| 16:35-16:55 | Early diagnosis and prediction of prognosis of colorectal cancer using microbiome | |
| 16:55-17:15 | Nutritional aspect in the prevention of colorectal cancer | |
| 17:15-17:25 | Discussion | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | An integrative approach to cancer based on precision medicine |
| 08:52-09:14 | Biomarkers in the diagnosis of gastric cancer | |
| 09:14-09:36 | Proteomics for PIVKA-II in HCC surveillance | |
| 09:36-09:58 | Esophageal impedance test: A new diagnostic approach for GERD and functional esophageal disorder | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Tailored therapy for refractory Helicobacter pylori infection |
| 10:37-10:59 | Personalized therapeutic approach to inflammatory bowel disease | |
| 10:59-11:21 | State of the art for liquid biomarkers in pancreatic cancer: An important consideration in the era of precision oncology | |
| 11:21-11:43 | The emerging role of liquid biopsy in digestive cancer | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Big data research in IBD: From real world data to real world evidence |
| 12:47-13:09 | Deep dive into bioinformatics in gastrointestinal cancer | |
| 13:09-13:31 | Development of therapeutic decision model in hepatology using artificial intelligence | |
| 13:31-13:53 | Risk prediction for malignant intraductal papillary mucinous neoplasm of the pancreas: logistic regression versus machine learning | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Early detection and stratification of gastric cancer through stem cell marker and miRNA |
| 14:32-14:54 | Overcoming peritoneal metastasis of colon cancer with STING-based immunotherapy | |
| 14:54-15:16 | Anti-tumor therapy of HCC using CAR T Cells derived from iPS cell | |
| 15:16-15:38 | Nano-bio system for the capture of pancreatic cancer cell secreted exosomes | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:20 | Changes in Korea's healthcare system and tasks of academic society in times of the COVID-19 Pandemic (코로나 이후 보건의료환경 변화와 학회의 대응) |
| 16:20-16:40 | Current status and future directions of review and assessment for gastrointestinal disease (소화기 질환의 심사 현황과 향후 방향) | |
| 16:40-17:00 | Necessity and prospect of reimbursement for magnifying endoscopy (확대 내시경 급여 필요성과 전망) | |
| 17:00-17:25 | Payment systems of health care: From the fee-for-service to various payment systems (행위별 수가제도에서 다양한 지불제도로) | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | The role of endoscopy in achalasia |
| 08:52-09:14 | The role of endoscopy and biopsy in chronic diarrhea with IBS-D | |
| 09:14-09:36 | The role of endoscopy in intestinal pseudo-obstruction, adult Hirschsprung's disease | |
| 09:36-09:58 | Anti-reflux endoscopic surgery for Gastroesophageal Reflux Disease | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | The microbiota of early life and developmental immunology |
| 10:37-10:59 | The effect of immunologic factors in IBS | |
| 10:59-11:21 | Microbial modulation of inflammation in IBD | |
| 11:21-11:43 | Immune response and gut microbiome in colorectal cancer | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Classification criteria for IgG4-related disease |
| 12:47-13:09 | Second line management of autoimmune hepatitis | |
| 13:09-13:31 | Novel immune therapy in IBD | |
| 13:31-13:53 | Novel therapy in primary sclerosing cholangitis | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Gastric cancer |
| 14:32-14:54 | Colon cancer | |
| 14:54-15:16 | Hepatocellular carcinoma | |
| 15:16-15:38 | Pancreatic cancer | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:45 | A unique phenotype of NAFLD: NAFLD with sarcopenia |
| 10:45-11:15 | Recent updates of clinical trials on NASH | |
| 11:15-11:45 | Influence of NAFLD on chronic hepatitis B and C | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-09:00 | Pathogenesis and outcomes of COVID-19 in patients with chronic liver disease |
| 09:00-09:30 | COVID-19 in liver transplantation | |
| 09:30-10:00 | COVID-19 vaccination for patients with chronic liver diseases | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:55 | Artificial intelligence-driven HCC prediction model for patients with chronic hepatitis B |
| 12:55-13:25 | Expanding treatment criteria for chronic hepatitis B | |
| 13:25-13:55 | Recent updates of clinical trials on functional cure of chronic hepatitis B | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Small intestinal dietary fructose metabolism prevents non-alcoholic fatty liver disease |
| 14:32-14:54 | Microbial metabolites entering into the liver: The role in diabetes and drug responses | |
| 14:54-15:16 | Fructose modulates leaky gut, endotoxemia and liver fibrosis through CYP2E1-mediated oxidative and Nitrative stress | |
| 15:16-15:38 | Role of diabetes on the risk of hepatocellular carcinoma in cirrhosis patients with NAFLD | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Clinical significance of obese and non-obese Fatty Liver Disease |
| 16:17-16:39 | Radiological assessment of NAFLD | |
| 16:39-17:01 | Endoscopic therapies for obesity in NAFLD | |
| 17:01-17:23 | Bariatric surgery in the management of obesity in NAFLD | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Abdominal ultrasound training know-how for internal medicine residents and gastroenterology fellows |
| 14:32-14:54 | Quality assurance in abdominal ultrasonography: Suggestion for certification of excellent ultrasound center | |
| 14:54-15:16 | A new horizon of ultrasound training for residents - POCUS | |
| 15:16-15:40 | Experience in operating ultrasound hands-on programs for internal medicine residents - Cardiology | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Ultrasound exam tips to reduce blind spots |
| 16:17-16:39 | Understandings for lower abdominal and kidney ultrasound | |
| 16:39-17:01 | Interesting ultrasound cases of pancreas cystic lesions | |
| 17:01-17:25 | Interesting ultrasound cases of hepatic tumors | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | High risk population for pancreatic cancer |
| 08:52-09:14 | Second-line chemotherapy for advanced pancreatic cancer | |
| 09:14-09:36 | Emerging molecular targets in pancreatic cancer | |
| 09:36-09:58 | Real-world data on the survival of patients with pancreatic cancer in Korea | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Indication, timing and safe technique of early/urgent ERCP in acute pancreatitis |
| 10:37-10:59 | EUS guided transmural drainage for pancreatitis related local complications | |
| 10:59-11:21 | Endoscopic transluminal necrosectomy for complicated walled off necrosis | |
| 11:21-11:43 | Risk and benefit of ERCP in pancreatitis related complications: Leakage, stricture and disconnection | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | How to maximize the effect of RFA for pancreatic tumor |
| 12:47-13:09 | The way to go more productive EUS-FNB | |
| 13:09-13:31 | The new era of EUS-guided diagnosis of pancreatic cyst | |
| 13:31-13:53 | Early diagnosis for pancreatic cancer | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Strategy for treatment of recurrent peptic ulcer |
| 16:17-16:39 | Risk factors of peptic ulcer bleeding | |
| 16:39-17:01 | Strategy for treatment of peptic ulcer bleeding | |
| 17:01-17:23 | Effect of Helicobacter pylori eradication in peptic ulcer | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Malignant bowel obstruction due to advanced GI cancer: Diagnosis and management |
| 08:52-09:14 | Breakthrough pain in GI cancer patients: Assessment and management | |
| 09:14-09:36 | Sleep disturbance in GI cancer patients: Assessment and management | |
| 09:36-09:58 | Caregiver in GI cancer patients: Important roles, burden and support | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:35 | Pathophysiology |
| 10:35-10:55 | Diagnostic approach | |
| 10:55-11:15 | Medical treatment | |
| 11:15-11:35 | Surgical treatment | |
| 11:35-11:45 | Discussion | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:45 | Pathophysiology |
| 12:45-13:05 | Diagnostic approach | |
| 13:05-13:25 | Overview of currently available therapeutic options | |
| 13:25-13:45 | Seoul consensus | |
| 13:45-13:55 | Discussion | |
| Date / Time | 299, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | IV hydration and protease inhibitors in acute pancreatitis |
| 14:32-14:54 | Bile acids in gallstones | |
| 14:54-15:16 | Antibiotics in acute cholangitis and cholecystitis | |
| 15:16-15:38 | Steroid and immunosuppressants in autoimmune pancreatitis | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Is chromoendoscopy still useful? |
| 08:52-09:14 | NBI, BLI, LCI and AFI with magnification | |
| 09:14-09:36 | Endocytoscopy: Japanese experience | |
| 09:36-09:58 | Rapid Fiber-Optic Raman Endoscopy: Immediate Medical Diagnosis in Gastrointestinal Tracts | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Lesion-based convolutional neural network in diagnosis of early gastric cancer |
| 10:37-10:59 | Computer-aided diagnosis for gastric mesenchymal tumors on EUS | |
| 10:59-11:21 | Computer-aided diagnosis of gastric neoplasms | |
| 11:21-11:43 | AI assisted esophageal cancer management | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | The strategy to enhance adequate bowel preparation for colonoscopy |
| 12:47-13:09 | Polypectomy strategy based on size and morphology | |
| 13:09-13:31 | Post-polypectomy surveillance: What is changed? | |
| 13:31-13:53 | Management of direct oral anticoagulants for patients undergoing polypectomy | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Advances in non-invasive strategies for CRC screening |
| 14:32-14:54 | IEE for detection and differentiation of colorectal neoplasia: NBI and BLI | |
| 14:54-15:16 | Automatic polyp detection in colonoscopy | |
| 15:16-15:38 | Deep learning for histological prediction of colon polyp | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:15 | Cholangioscopy |
| 16:15-16:35 | Pancreatoscopy | |
| 16:35-16:55 | Intraductal ultrasonography | |
| 16:55-17:15 | Confocal laser endomicroscopy | |
| 17:15-17:25 | Case based discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | How to make a fun and memorable lecture on the gastroenterology? |
| 16:17-16:39 | The introduction of Asan Medical Center EGD education program with the simulators for residents and fellows | |
| 16:39-17:01 | Research ethics for gastroenterologists | |
| 17:01-17:23 | Lessons given to gastroenterologists in clinical practice through medical appraisal | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | What is the best among various precut access including primary precut for ERCP? |
| 08:52-09:14 | RFA for palliative treatment of unresectable extrahepatic cholangiocarcinoma: Current status, future perspective and challenges | |
| 09:14-09:36 | Head-to-head comparison of developed EUS-guided biopsy needles | |
| 09:36-09:58 | EUS-acquired pancreatic cyst fluid analysis, where we are and where we go | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | What is your choice for removing large sessile serrated lesions: Piecemeal or en bloc? |
| 10:37-10:59 | Small bowel endoscopy for unexplained iron deficiency anemia, should we do? | |
| 10:59-11:21 | Modified EMR or ESD for rectal neuroendocrine tumors, which one is better? | |
| 11:21-11:43 | Is radical surgery mandatory for deep submucosal colorectal cancer? | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Multi-omics analysis of endoscopy-derived pancreas organoids reveal novel targets for the treatment of pancreas ductal adenocarcinoma |
| 12:47-13:09 | Discovery of tumor heterogeneity with endoscopic minimal specimens | |
| 13:09-13:31 | Diagnosis of bile duct cancer: Novel brushing cytology or forceps biopsy | |
| 13:31-13:53 | EUS-guided through-the-needle microforceps biopsy for pancreas cystic lesions | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Indications and techniques of PEG |
| 14:32-14:54 | Complications related to PEG | |
| 14:54-15:16 | Percutaneous Radiological Gastrostomy and Jejunostomy | |
| 15:16-15:38 | Laparoscopic gastrostomy or jejunostomy in challenging cases | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:47 | Preoperative inspection and localization of early gastric cancer |
| 12:47-13:09 | Management of postoperative complications: Focusing on collaboration with gastroenterologists | |
| 13:09-13:31 | Nutritional management before and after gastrectomy | |
| 13:31-13:53 | Eradication of Helicobacter pylori after subtotal gastrectomy: Is it necessary? | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | Role of endoscopy in the diagnosis of subepithelial tumor at upper GI tract |
| 14:32-14:54 | Multiparametric Imaging Approaches for Gastric GIST | |
| 14:54-15:16 | What are indications for endoscopic resection of gastric GIST? | |
| 15:16-15:38 | Laparoscopic and endoscopic cooperative surgery for treatment of gastric GIST | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:17 | Pathology, classification, and grading of gastrointestinal NET |
| 16:17-16:39 | Management of gastric NET | |
| 16:39-17:01 | Management of duodenal NET | |
| 17:01-17:23 | Systemic treatment for advanced gastrointestinal NEN | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Predicting therapeutic efficacy using receptor-targeted activatable probes |
| 08:52-09:14 | Clinical application of proteomics/metabolomics | |
| 09:14-09:36 | Emerging prospects of exosome: Regulation of cancer immune microenvironment | |
| 09:36-09:58 | Current and future pharmacological and surgical treatment options for NAFLD | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Proteogenomics analysis of human pancreatic ductal adenocarcinoma |
| 10:37-10:59 | Enhancing the immune response to pancreatic cancer: Lessons from the tumor microenvironment | |
| 10:59-11:21 | New immuno-oncology agents for patients with pancreatobiliary cancer | |
| 11:21-11:43 | Real-world experience of immune checkpoint blockade therapy for pancreatobiliary cancer | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:45 | Early diagnosis and proper monitoring of IBD in pediatrics and adolescents |
| 12:45-13:05 | Growth failure in pediatric and adolescent IBD patients: Significance and management | |
| 13:05-13:25 | Proper vaccination strategy for IBD patients | |
| 13:25-13:45 | Key elements for successful transitional care in IBD | |
| 13:45-13:55 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 15:55-16:15 | Update on management of IBD during pregnancy |
| 16:15-16:35 | Diagnosis and management of recurrent C. difficile infection in IBD | |
| 16:35-16:55 | Management of acute severe ulcerative colitis | |
| 16:55-17:15 | Diagnosis and management of extraintestinal manifestations in IBD | |
| 17:15-17:25 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:32 | The normal development of infant gut microbiota: Maternal and fetal factors |
| 14:32-14:54 | Pediatric GERD from infants to adolescents: Should we test? / Should we treat? | |
| 14:54-15:16 | Gut microbiota and childhood obesity | |
| 15:16-15:38 | Guidelines for the management of helicobacter pylori: What are the differences between adults and children? | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:50 | Esophageal HRM and esophagography |
| 08:50-09:10 | 24hr pH and impedance | |
| 09:10-09:30 | Intestinal transit and breath test | |
| 09:30-09:50 | Anorectal HRM and defecography | |
| 09:50-10:00 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:35 | Gut microbiota & IBS |
| 10:35-10:55 | Infection & IBS | |
| 10:55-11:15 | Diet therapies for IBS | |
| 11:15-11:35 | Medical treatment for IBS | |
| 11:35-11:45 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 14:10-14:30 | Tip for the diagnosis and treatment of protein-losing enteropathy |
| 14:30-14:50 | Review of current knowledge on absorptive disorders | |
| 14:50-15:10 | Optimal approach for small bowel bleeding | |
| 15:10-15:30 | Newest perspective in NSAID-induced enteropathy | |
| 15:30-15:40 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 12:25-12:50 | Transparency and ethics in scholarly publishing |
| 12:50-13:15 | Clinical endoscopy editors' advices for writing good response | |
| 13:15-13:40 | Strategy to receive acceptance letter from SCI journal | |
| 13:40-13:55 | Discussion | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 08:30-08:52 | Definition, epidemiology, and co-morbidities: Focusing on the changes |
| 08:52-09:14 | Diagnostic algorithm for identifying high-risk patients in NAFLD | |
| 09:14-09:36 | Updates on non-invasive assessment of liver steatosis and fibrosis | |
| 09:36-09:58 | Current and future pharmacological and surgical treatment options | |
| Date / Time | 300, | |
|---|---|---|
| Channel | ||
| Speakers | 10:15-10:37 | Guidelines for gastric cancer screening |
| 10:37-10:59 | Results from the national cancer screening program for gastric cancers in Korea | |
| 10:59-11:21 | Guidelines for colorectal cancer screening | |
| 11:21-11:43 | Results from the national cancer screening program for colorectal cancers in Korea (including population-based colonoscopy screening) | |